UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000020255 |
|---|---|
| Receipt number | R000023386 |
| Scientific Title | The molecular biologic chracteristic analysis of primary fallopian tube carcinoma. |
| Date of disclosure of the study information | 2016/02/01 |
| Last modified on | 2016/12/26 13:48:50 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
The molecular biologic chracteristic analysis of primary fallopian tube carcinoma.
Acronym
The molecular biologic chracteristic analysis of primary fallopian tube carcinoma.
Scientific Title
The molecular biologic chracteristic analysis of primary fallopian tube carcinoma.
Scientific Title:Acronym
The molecular biologic chracteristic analysis of primary fallopian tube carcinoma.
Region
| Japan |
Condition
Condition
primary fallopian tube carcinoma
Classification by specialty
| Obstetrics and Gynecology |
Classification by malignancy
Malignancy
Genomic information
YES
Objectives
Narrative objectives1
Molecular biologic characteristic analysis of primary fallopian tube carcinoma.
Basic objectives2
Others
Basic objectives -Others
It is aimed for the application to a diagnosis in examination, the preoperation of the outbreak factor of uterine tube cancer by analyzing the molecular biologic characteristic of primary fallopian tube carcinoma.
Trial characteristics_1
Others
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
Clarify the molecular biologic characteristic of primary fallopian tube carcinoma.
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 40 | years-old | < |
Age-upper limit
| 90 | years-old | >= |
Gender
Female
Key inclusion criteria
primary fallopian tube carcinoma
primary peritoneal carcinoma
high grade serous ovarian carcinoma
Key exclusion criteria
There is particularly no it.
Target sample size
60
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Hideki Tokunaga |
Organization
TOHOKU UNIVERSITY
Division name
Department of Gynecology and Obsterics
Zip code
Address
1-1, Seiryo-machi, Aoba-ku, Sendai
TEL
022-717-7251
tokunagahideki@med.tohoku.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Shoko Sakurada |
Organization
TOHOKU UNIVERSITY
Division name
Department of Gynecology and Obstetrics
Zip code
Address
1-1, Seiryo-machi, Aoba-ku, Sendai
TEL
022-717-7251
Homepage URL
s.sakurada@med.tohoku.ac.jp
Sponsor or person
Institute
Department of Gynecology and Obstetrics , Tohoku University
Institute
Department
Personal name
Funding Source
Organization
Department of Gynecology and Obstetrics , Tohoku University
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2016 | Year | 02 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2016 | Year | 02 | Month | 01 | Day |
Date of IRB
Anticipated trial start date
| 2016 | Year | 02 | Month | 01 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
We detect copy number variations and BRCA/p53 about a primary fallopian tube carcinoma, a peritoneum cancer, a high atypical degree ovary serosity adenocarcinoma.
Management information
Registered date
| 2015 | Year | 12 | Month | 17 | Day |
Last modified on
| 2016 | Year | 12 | Month | 26 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023386
